UAB Eletis Medica Successfully Completes Safety Monitoring for Phase I Clinical Trial
Eletis Medica is pleased to announce the successful completion of safety monitoring for Phase I clinical trial. This significant milestone marks a crucial step forward in the development of groundbreaking medical treatments.
Phase I clinical trials represent the initial stage of the rigorous testing process for new drugs or treatments. They primarily focus on assessing the safety, tolerability, and dosage levels of the experimental intervention in a small group of healthy volunteers or patients. This phase is crucial in determining the potential risks and side effects associated with the treatment under investigation.
Phase I clinical trial involved an innovative therapeutic approach designed to address a pressing medical need. Throughout the trial, diligent safety monitoring measures were implemented to ensure the well-being and welfare of all participants. The trial’s successful completion signifies that the experimental treatment has demonstrated an acceptable safety profile and paves the way for further advancements in its development.
The positive outcomes from the Phase I clinical trial encourage companies to proceed to the next stage of development. The companies remain committed to upholding the highest standards of patient safety and scientific rigor as it progresses towards bringing innovative and effective treatments to those in need.
Clinical trial
Eletis Medica has joined the phase I clinical trial as a safety partner.
Our pharmacovigilance team will take care of the Investigational New Drug (IND) Safety process and design answers to the specific research questions related to the safety of the medical product.
Medicines import
Eletis Medica has signed a service agreement with the TecEx for import/export of Investigational Medicinal Products (IMP) and Medicines for Clinical trials. Our experience in importing medicines from non-EU countries will help sponsors and CRO to manage clinical trials and import of IMP and investigational medicines.
Support to child welfare center “Shelter”
Eletis Medica has committed to ensuring the prevention of vitamin D3 throughout the year for children affected by the war in Ukraine. We want to help take care not only of their normal functioning of the immunity system or healthy teeth, but also of their psychological state and leisure. Therefore, from each packaging of the brand Oilidin (vitamin D3) sold, we devote part of the funds to creating an emotional environment for children.